Rating Change
Evercore ISI Group reiterated its Outperform rating on Vir Biotechnology, Inc. (NASDAQ:VIR) on November 10, 2026.
Evercore ISI Group reiterated its Outperform rating on Vir Biotechnology, Inc. (NASDAQ:VIR) on November 10, 2026.

At publication ·
Vir Biotechnology, Inc. (NASDAQ:VIR) · reiterate
At a glance
Evercore ISI Group reiterated its Outperform rating on Vir Biotechnology, Inc. (NASDAQ:VIR) on November 10, 2026.
Vir Biotechnology, Inc. operates in the Healthcare sector. The stock currently trades at $13.15 with a market capitalization of $923.0M. The stock has gained 149.4% over the past 52 weeks.
Analyst coverage from Evercore ISI Group provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Vir Biotechnology, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 10, 2026 | Morgan Stanley | Overweight | N/A |
| Nov 10, 2026 | Evercore ISI Group | Outperform | N/A |
| Nov 09, 2026 | Needham | Buy | N/A |
| Nov 09, 2026 | HC Wainwright & Co. | Buy | N/A |
| Nov 05, 2026 | Needham | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View VIR Stock Page
A rating of Outperform from Evercore ISI Group reflects the analyst's outlook on Vir Biotechnology, Inc. (NASDAQ:VIR). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the VIR forecast page.
Current market data
NASDAQ · VIR
$9.58
Down: -$0.38 · -3.82%
Live quote updated
Keep reading
analyst ·
sec_filing ·
analyst ·
sec_filing ·